Prospect Biosystems focuses on providing biomarker solutions for drug discovery, diagnostics and disease management. The company develops bioanalytical instrumentations, reagents, and biomarker evaluation and validation platforms. Prospect also provides biomarker evaluation and extensive proteomics services.

The Company’s patent-pending Edge™ Technology platform is a breakthrough fractionation and separation technology that allows scientists, researchers, and clinicians, including physicians and surgeons to rapidly separate highly complex biological samples to find, analyze, and evaluate biomarkers or protein targets, enabling them to develop innovative solutions to detect, treat, and manage diseases.

The Edge 200™ Separation System can be used as a standalone instrument or positioned upstream of a wide range of analytical instrumentations such as mass spectrometers, HPLCs, gel electrophoresis, micro-arrays, etc. The Edge 200 does not compete with other systems in the bio-analytical landscape - it complements and adds value to all downstream analytical processes.
The Company markets and distributes its products and services directly and through distributors and agents worldwide. (Click here to find a distributor in your area)

Prospect Biosystems was founded in 2006. Its office and laboratory are located at Enterprise Development Center in Newark, NJ. It is on the campus of New Jersey Institute of Technology.

• Prospect Biosystems' management team
• meet our collaborators
• locate a distributor near you
• Join Prospect's team